April 2007 in “The Journal of Urology” Finasteride reduces bleeding risk during prostate surgery.
January 2006 in “Revista Argentina de Urología” Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.
August 2021 in “The Journal of Urology” Finasteride use is strongly linked to sexual dysfunction, especially in young men treating hair loss.
90 citations
,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
2 citations
,
July 2025 in “Discover Chemistry.” Alstonia boonei phytochemicals show promise as alternative treatments for BPH with fewer side effects than current drugs.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
November 2024 in “Journal of Investigative Dermatology” 39 citations
,
February 2011 in “The Prostate/The prostate” Some men's prostate tissues have low enzyme levels due to genetic changes, possibly affecting treatment for prostate enlargement.
2 citations
,
August 2016 in “Experimental Dermatology” Finasteride treats baldness but may cause lasting sexual side effects.
28 citations
,
August 2014 in “Cancer Causes & Control” Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.
29 citations
,
May 2011 in “Journal of Cataract and Refractive Surgery” Finasteride may cause cataracts and floppy-iris syndrome.
January 2004 in “Data Archiving and Networked Services (DANS)” Finasteride blocks progesterone's effect on brain activity linked to epilepsy.
1 citations
,
April 2020 in “Journal of The American Academy of Dermatology” 5ARI treatment improves hair growth in older men with minimal side effects.
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
August 2024 in “Journal of Personalized Medicine” Tamsulosin increases the risk of floppy iris during eye surgery.
2 citations
,
January 2023 in “Uro” UHP-sCESr is as effective as HESr for treating BPH symptoms.
14 citations
,
April 2024 in “The Journal of Steroid Biochemistry and Molecular Biology” 5α-reductases increase epitestosterone's effect on androgen receptors.
149 citations
,
January 2011 in “Nature reviews. Urology” Hormonal interactions, especially involving DHT and estrogen, play a key role in BPH development and treatment.
September 2004 in “Evidencia actualizacion en la práctica ambulatoria” Using finasteride and doxazosina together works better for treating benign prostatic hyperplasia than using just one.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
April 2010 in “Nature Reviews Urology” 18 citations
,
June 2017 in “Journal of the neurological sciences” Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.
34 citations
,
December 2021 in “Journal of Clinical Medicine” Men with BPH should discuss potential sexual side effects with doctors before treatment, as some treatments can affect ejaculation.
4 citations
,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
64 citations
,
June 1995 in “Steroids” Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.
December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
January 2002 in “Chinese Journal of Hospital Pharmacy” Finasteride tablets are stable and effective for treating benign prostatic hyperplasia.
December 2003 in “British Journal of Urology” 8 citations
,
March 2012 in “Mass spectrometry letters” The S9 fraction with GC-IDMS is effective for measuring 5α-reductase activity.